Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, shared a post on LinkedIn:
“This week at MD Anderson Cancer Center, I had the chance to reconnect with oncologists, across tumor types, who are shaping the future of cancer care.
We reviewed where Bristol Myers Squibb‘s pipeline is headed across oncology, hematology and cell therapy, how we can accelerate the right studies, and what it takes to bring meaningful options to patients faster. MD Anderson’s depth in clinical research, and the caliber of its teams, make it an indispensable collaborator in that work. That’s why it is home to the largest cancer clinical trial programs in the U.S.
Conversations like these reaffirm our focus as we work to develop new medicines for patients who need them the most. Thank you to the MD Anderson faculty – including S. Daniel Haldar, Van Morris, Xiuning Le, Jordi Rodón and others – for your candor, collaboration, and shared urgency to improve outcomes for people living with cancer.”
Other articles featuring Cristian Massacesi on OncoDaily.
